SELLAS Life Sciences Group, Inc. (SLS) Hit All-Time Low at $3.24 on Jun, 29

June 29, 2018 - By Alberta Moore

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) reached all time low on Jun, 29 touching $3.24. Our target is $3.08. It was reported by Barchart.com. The company has $21.56M market cap. At $3.08 stock target, the company valuation changes by $1.08 million less.

Ticker’s shares touched $3.24 during the last trading session after 8.22% change.SELLAS Life Sciences Group, Inc. has volume of 137,647 shares. Since June 29, 2017 SLS has declined 71.31% and is downtrending. SLS underperformed the S&P 500 by 83.88%.

For more SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) news published briefly go to: Benzinga.com, Benzinga.com, Nasdaq.com, Benzinga.com or Nasdaq.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut” published on June 28, 2018, “54 Biggest Movers From Yesterday” on June 27, 2018, “Mid-Morning Market Update: Markets Open Higher; Lennar Tops Q2 Estimates” with a publish date: June 26, 2018, “40 Stocks Moving In Tuesday’s Mid-Day Session” and the last “SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVaxâ„¢ (nelipepimut-S) Study in Combination with …” with publication date: June 01, 2018.

SELLAS Life Sciences Group, Inc., a development-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications.The company has $21.56 million market cap. The company's lead product candidate is galinpepimut-S, a cancer immunotherapeutic agent for the treatment of hematologic cancers and solid tumor indications, including acute myeloid leukemia, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, immune combo, and chronic myelogenous leukemia.Currently it has negative earnings. It also develops NEUVAX, which is in Phase II clinical trial for the treatment of breast cancer; and Anagrelide controlled release, which has completed various clinical trials for the treatment of thrombocythemia.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: